Development of (177)Lu-scFvD2B as a Potential Immunotheranostic Agent for Tumors Overexpressing the Prostate Specific Membrane Antigen

The clinical translation of theranostic (177)Lu-radiopharmaceuticals based on inhibitors of the prostate-specific membrane antigen (PSMA) has demonstrated positive clinical responses in patients with advanced prostate cancer (PCa). However, challenges still remain, particularly regarding their pharm...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Sci Rep
Egile Nagusiak: Carpanese, Debora, Ferro-Flores, Guillermina, Ocampo-Garcia, Blanca, Santos-Cuevas, Clara, Salvarese, Nicola, Figini, Mariangela, Fracasso, Giulio, De Nardo, Laura, Bolzati, Cristina, Rosato, Antonio, Meléndez-Alafort, Laura
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Nature Publishing Group UK 2020
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7283306/
https://ncbi.nlm.nih.gov/pubmed/32518372
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-020-66285-2
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak